Perspectives on generative chemistry – potential and reality
Have advances in AI and deep learning reached a threshold whereby generative chemistry methods are redefining drug design? This webinar…
This symposium was hosted by Optibrium and Collaborative Drug Discovery (CDD) with presentations by Peter Monecke (Sanofi) and Lizbé Koekemoer (The Structural Genomics Consortium), demonstrations by Tamsin Mansley (Optibrium) and Charlie Weatherall (CDD), and concluding with a Round-table discussion on the next frontiers of drug discovery informatics, with Matt Segall (Optibrium) and Barry Bunin (CDD) .
Advances in informatics technology are inspiring a new generation of innovative products that streamline and enhance the efficiency and productivity of drug discovery software. The second symposium, organised by Optibrium and Collaborative Drug Discovery, brought together speakers at the forefront of drug research and development, and demonstrations of cutting-edge technologies for small molecule design, optimisation and data-analysis.
Meet the speakers
Peter Monecke
Principal Scientist in Digital Toxicology, Sanofi
Lizbé Koekemoer, PhD
The Structural Genomics Consortium
Tamsin Mansley, PhD
Global Head of Application Science, Optibrium
Charlie Weatherall
Director of Customer Engagement, Collaborative Drug Discovery
Matt Segall, PhD
CEO, Optibrium
Barry Bunin, PhD
CEO, Collaborative Drug Discovery
More informatics in drug discovery resources
3D ligand-based drug design: webinar
In this webinar, we demonstrate intuitive workflows for 3D ligand-based drug design
AI in early drug discovery: from promise to practice
In this webinar, Jeff Blaney (Senior Director of Discovery Chemistry, Genentech), Darren Green (Head of Cheminformatics & Data Science, GlaxoSmithKline), Julian Levell (Head of Discovery, New Equilibrium Biosciences), Matthew Segall (CEO, Optibrium) discuss the state of AI in early drug discovery from hit to preclinical candidate and share their experiences with and expectations of AI, including predictive modelling, synthesis prediction, and generative chemistry. Hear about the successes of AI drug discovery and an outlook on what AI needs to achieve to really transform the industry.
